Literature DB >> 20623626

Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells.

Tariq Shah1, Flonne Wildes, Marie-France Penet, Paul T Winnard, Kristine Glunde, Dmitri Artemov, Ellen Ackerstaff, Barjor Gimi, Samata Kakkad, Venu Raman, Zaver M Bhujwalla.   

Abstract

A direct correlation exists between increased choline kinase (Chk) expression, and the resulting increase of phosphocholine levels, and histological tumor grade. To better understand the function of Chk and choline phospholipid metabolism in breast cancer we have stably overexpressed one of the two isoforms of Chk-alpha known to be upregulated in malignant cells, in non-invasive MCF-7 human breast cancer cells. Dynamic tracking of cell invasion and cell metabolism were studied with a magnetic resonance (MR) compatible cell perfusion assay. The MR based invasion assay demonstrated that MCF-7 cells overexpressing Chk-alpha (MCF-7-Chk) exhibited an increase of invasion relative to control MCF-7 cells (0.84 vs 0.3). Proton MR spectroscopy studies showed significantly higher phosphocholine and elevated triglyceride signals in Chk overexpressing clones compared to control cells. A test of drug resistance in MCF-7-Chk cells revealed that these cells had an increased resistance to 5-fluorouracil and higher expression of thymidylate synthase compared to control MCF-7 cells. To further characterize increased drug resistance in these cells, we performed rhodamine-123 efflux studies to evaluate drug efflux pumps. MCF-7-Chk cells effluxed twice as much rhodamine-123 compared to MCF-7 cells. Chk-alpha overexpression resulted in MCF-7 human breast cancer cells acquiring an increasingly aggressive phenotype, supporting the role of Chk-alpha in mediating invasion and drug resistance, and the use of phosphocholine as a biomarker of aggressive breast cancers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20623626      PMCID: PMC3115627          DOI: 10.1002/nbm.1510

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  45 in total

1.  Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells.

Authors:  E Ackerstaff; B R Pflug; J B Nelson; Z M Bhujwalla
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

2.  Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: the Metabolic Boyden Chamber.

Authors:  U Pilatus; E Ackerstaff; D Artemov; N Mori; R J Gillies; Z M Bhujwalla
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

3.  Real-time measurements of cellular oxygen consumption, pH, and energy metabolism using nuclear magnetic resonance spectroscopy.

Authors:  U Pilatus; E Aboagye; D Artemov; N Mori; E Ackerstaff; Z M Bhujwalla
Journal:  Magn Reson Med       Date:  2001-05       Impact factor: 4.668

4.  Expression of human choline kinase in NIH 3T3 fibroblasts increases the mitogenic potential of insulin and insulin-like growth factor I.

Authors:  T Chung; J S Huang; J J Mukherjee; K S Crilly; Z Kiss
Journal:  Cell Signal       Date:  2000-05       Impact factor: 4.315

Review 5.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

Authors:  Alfred H Schinkel; Johan W Jonker
Journal:  Adv Drug Deliv Rev       Date:  2003-01-21       Impact factor: 15.470

6.  Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers.

Authors:  Ana Ramírez de Molina; Agustín Rodríguez-González; Ruth Gutiérrez; Luis Martínez-Piñeiro; José Sánchez; Félix Bonilla; Rafael Rosell; Juan Lacal
Journal:  Biochem Biophys Res Commun       Date:  2002-08-23       Impact factor: 3.575

7.  In vivo 1H-MRS evaluation of malignant and benign breast diseases.

Authors:  Jong-Ki Kim; Sung-Hwan Park; Hyun Mee Lee; Young-Hwan Lee; Nak-Kwan Sung; Duck-Soo Chung; Ok-Dong Kim
Journal:  Breast       Date:  2003-06       Impact factor: 4.380

8.  Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.

Authors:  Ana Ramírez de Molina; Ruth Gutiérrez; Maria Angeles Ramos; José María Silva; Javier Silva; Félix Bonilla; José Javier Sánchez; Juan Carlos Lacal
Journal:  Oncogene       Date:  2002-06-20       Impact factor: 9.867

9.  Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.

Authors:  Katrina M Comerford; Timothy J Wallace; Jörn Karhausen; Nancy A Louis; Michael C Montalto; Sean P Colgan
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

10.  Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer.

Authors:  N R Jagannathan; M Kumar; V Seenu; O Coshic; S N Dwivedi; P K Julka; A Srivastava; G K Rath
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

View more
  35 in total

1.  Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells.

Authors:  Tariq Shah; Ioannis Stasinopoulos; Flonne Wildes; Samata Kakkad; Dmitri Artemov; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2011-09-22       Impact factor: 4.044

2.  Targeting choline phospholipid metabolism: GDPD5 and GDPD6 silencing decrease breast cancer cell proliferation, migration, and invasion.

Authors:  Maria Dung Cao; Menglin Cheng; Asif Rizwan; Lu Jiang; Balaji Krishnamachary; Zaver M Bhujwalla; Tone F Bathen; Kristine Glunde
Journal:  NMR Biomed       Date:  2016-06-30       Impact factor: 4.044

3.  Molecular causes of elevated phosphoethanolamine in breast and pancreatic cancer cells.

Authors:  Tariq Shah; Balaji Krishnamachary; Flonne Wildes; Jannie P Wijnen; Kristine Glunde; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2018-06-21       Impact factor: 4.044

Review 4.  MRI and MRS of intact perfused cancer cell metabolism, invasion, and stromal cell interactions.

Authors:  Marie-France Penet; Tariq Shah; Flonne Wildes; Balaji Krishnamachary; Santosh K Bharti; Jesus Pacheco-Torres; Dmitri Artemov; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2019-01-28       Impact factor: 4.044

5.  Direct inhibition of choline kinase by a near-infrared fluorescent carbocyanine.

Authors:  Sean P Arlauckas; Anatoliy V Popov; Edward J Delikatny
Journal:  Mol Cancer Ther       Date:  2014-07-15       Impact factor: 6.261

Review 6.  Applications of high-resolution magic angle spinning MRS in biomedical studies II-Human diseases.

Authors:  Christopher Dietz; Felix Ehret; Francesco Palmas; Lindsey A Vandergrift; Yanni Jiang; Vanessa Schmitt; Vera Dufner; Piet Habbel; Johannes Nowak; Leo L Cheng
Journal:  NMR Biomed       Date:  2017-09-15       Impact factor: 4.044

Review 7.  Proton MR spectroscopy in the breast: Technical innovations and clinical applications.

Authors:  Reza Fardanesh; Maria Adele Marino; Daly Avendano; Doris Leithner; Katja Pinker; Sunitha B Thakur
Journal:  J Magn Reson Imaging       Date:  2019-03-07       Impact factor: 4.813

Review 8.  Choline metabolism-based molecular diagnosis of cancer: an update.

Authors:  Kristine Glunde; Marie-France Penet; Lu Jiang; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Expert Rev Mol Diagn       Date:  2015-04-28       Impact factor: 5.225

9.  Phospholipase D1 and choline kinase-α are interactive targets in breast cancer.

Authors:  Mayur Gadiya; Noriko Mori; Maria D Cao; Yelena Mironchik; Samata Kakkad; Ingrid S Gribbestad; Kristine Glunde; Balaji Krishnamachary; Zaver M Bhujwalla
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

10.  Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas.

Authors:  Kayvan R Keshari; Renuka Sriram; Bertram L Koelsch; Mark Van Criekinge; David M Wilson; John Kurhanewicz; Zhen J Wang
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.